- Dr. Mackler Brings Immunology and Regulatory Expertise to the SAB -
CARLSBAD, Calif., Nov. 16 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming
a leading immune-based therapy company in HIV and multiple sclerosis,
announced today that Bruce Mackler, Ph.D., J.D., a Food and Drug (FDA)
practice shareholder in the law firm of Heller Ehrman White & McAuliffe LLP
and immunologist/immunochemist, has joined the Company's HIV Scientific
Advisory Board (SAB). Dr. Mackler brings more than 25 years' experience in
regulatory affairs to the Company's SAB.
"Dr. Mackler's impressive accomplishments and regulatory expertise will be
an asset to the Company and we look forward to working closely with him,"
commented John N. Bonfiglio, Ph.D., President and Chief Executive Officer of
The Immune Response Corporation. "His input and guidance will be especially
valuable as we move toward commercialization of REMUNE(R) and IR103."
"I am honored to join the illustrious group of HIV experts on The Immune
Response Corporation's HIV Scientific Advisory Board. Both REMUNE(R) and
IR103 are showing promise so I am very pleased to be involved with the Company
at this stage," stated Dr. Mackler.
Dr. Bruce F. Mackler, a Food & Drug (FDA) practice shareholder with the
law firm of Heller Ehrman White & McAuliffe LLP, is an
immunologist/immunochemist with some 100 published scientific
articles/abstracts. Dr. Mackler received his J.D. from the South Texas
College of Law (magna cum laude, 1979), his Ph.D. (Immunology/Microbiology)
from the University of Oregon Medical School (1970), his M.S.
(Immunology/Microbiology) from the Pennsylvania State University (1965), and
his B.A. (Biology) from Temple University (1964). After receiving his Ph.D. he
was post-doctorate at the Kennedy Institute of Rheumatology, in London
(1970-71), a visiting fellow at the Sandoz Institute in Vienna, Austria
(1971), then a visiting scientist and contract employee at the National
Institutes of Health (1971-72) and an Associate Professor at the University
Health Science Center and Dental Science Institute. He is a member of the
District of Columbia Bar.
The Company's Scientific Advisory Board was formed in 2003 to help guide
the development of immune-based therapies for HIV. Other board members are:
Gilbert S. Omenn, MD, PhD (Chairman)
Professor of Internal Medicine, Human Genetics and Public Health,
University of Michigan
Mario Clerici, MD
Chair of Immunology, University of Milan, Italy
Eduardo Fernandez-Cruz, MD
Professor and Head of the Department of Immunology, University General
Hospital Gregorio Maranon, Madrid, Spain
Brian G. Gazzard, MA, MD, FRCP
Professor, Chelsea and Westminster Hospital, London, England
Peter L. Salk, MD
Vice President and Scientific Director of the Jonas Salk Foundation
Paul A. Volberding, MD
Professor and Vice Chair of the Department of Medicine at the
University of California, San Francisco, and Chief of the Medical Service
at the San Francisco Veterans Administration Medical Center
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical
company dedicated to becoming a leading immune-based therapy company in HIV
and multiple sclerosis (MS). The Company's HIV products are based on its
patented whole-killed virus technology, co-invented by Company founder Dr.
Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently in Phase
II clinical trials, is being developed as a first-line treatment for people
with early-stage HIV. We have initiated development of a new immune-based
therapy, IR103, which incorporates a second-generation immunostimulatory
oligonucleotide adjuvant and is currently in Phase I/II clinical trials in
Canada and the United Kingdom.
The Immune Response Corporation is also developing an immune-based therapy
for MS, NeuroVax(TM), which is currently in Phase II and has shown potential
therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation at http://www.imnr.com
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern
and successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of
REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical
trials. These risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual Report on
Form 10-K for the year ended December 31, 2003, and its subsequent Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
MEDIA CONTACT: INVESTOR CONTACT:
Laura Silver Michael K. Green
Sam Brown Inc. Corporate Communications Chief Financial Officer
310-551-9940 760-431-7080
silver@sambrown.com info@imnr.com
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, Laura Silver of Sam Brown Inc.
Corporate Communications, +1-310-551-9940, silver@sambrown.com,
for The Immune Response Corporation; or Investors, Michael K.
Green, Chief Financial Officer of The Immune Response
Corporation, +1-760-431-7080, info@imnr.com
|
